Behavioral Health Medication Reference
Search 244 medications across psychopharmacology, cognition, wakefulness, sleep,
chronic pain, hormone therapy, and substance-use treatment. Search by drug name (generic or brand),
class, approved or off-label use, mechanism, pharmacogenomics, DEA schedule, or sleep effect — or any term.
This page was developed primarily as a quick reference within my own clinical work —
to help inform clients on talking points to raise with their medical provider.
Clinical basis. Information is informed by Stahl’s Essential Psychopharmacology
(Stephen M. Stahl); The Therapist’s Guide to Psychopharmacology, 3rd ed. (Patterson, Griffith &
Edwards); Kryger’s Principles and Practice of Sleep Medicine, Ch. 53 — Drugs That Disturb Sleep
and Wakefulness (Tables 53.1–53.12; source of the sleep-architecture, residual-sedation and
nightmare/RLS/RBD data); and Baldacci A, Saguin E, Balcerac A, et al., Pharmacogenetic Guidelines for
Psychotropic Drugs (Pharmaceutics 2023;15:2540; source of the CYP2D6/2C19/2B6/3A4 phenotype definitions,
CPIC/DPWG dose-adjustment grids, FDA pharmacogenetic associations and phenoconversion) — cross-referenced
with FDA prescribing information (DailyMed).
Disclaimer
For educational purposes only. Intended to inform therapists and clinicians in behavioral
health, and to help individuals in medication management better understand the medications they are taking. It is
not medical advice and not a substitute for professional clinical judgment or official FDA labeling.
Do not use it to start, stop, or change any medication — always consult a qualified prescriber. Doses are typical
adult ranges; pharmacogenomic guidance reflects CPIC/DPWG/FDA sources current to the references above and changes over
time; sleep-architecture entries derive from Kryger’s tables where data exist and from class pharmacology where
they do not. DEA schedules and Utah notes are general regulatory context, not legal advice, and can
change — verify against current DEA and Utah DOPL rules.
Reading the badges, sleep symbols & columns
DEA schedule & Utah
- C-II–C-V federal control (C-II most restricted). Rx non-controlled Rx · OTC over-the-counter · Investigational not FDA-approved.
- Utah parallels the DEA schedules and tracks Schedule II–V in its Controlled Substance Database (CSD). Gabapentin is non-controlled but CSD-reported.
Sleep symbols (Kryger Table 53.2)
- ↑ Increase · ↓ Decrease · ↔ No change
- ↔↓/↔↑ inconsistent · ↓↓ marked decrease · ? unclear · blank = no PSG data
Sleep columns
- Sleep Latency — time to fall asleep (↓ desirable in insomnia).
- Sleep Continuity — sleep efficiency (↑ desirable).
- SWS — slow-wave (deep, N3) sleep; few drugs raise it.
- REM — most antidepressants/all MAOIs suppress it; orexin antagonists & cholinesterase inhibitors raise it.
- Residual Sedation — next-day carryover, – to ++++ (Kryger 53.3–53.4).
No medications match. Try a broader term
(a drug name, “insomnia,” “CYP2D6,” “schedule IV,” or “REM”) or clear the filters.